Synonyms: Epclusa® (sofosbuvir + velpatasvir) | GS-5816 | GS5816 | Vosevi® (sofosbuvir + velpatasvir + voxilaprevi)
velpatasvir is an approved drug (EMA & FDA (2016))
Compound class:
Synthetic organic
Comment: Velpatasvir is a direct-acting inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex [2]. It targets viral RNA replication and viron assembly.
|
|
References |
1. Lawitz E, Freilich B, Link J, German P, Mo H, Han L, Brainard DM, McNally J, Marbury T, Rodriguez-Torres M. (2015)
A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus. J Viral Hepat, 22 (12): 1011-9. [PMID:26183611] |
2. Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. (2014)
Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol, 20 (11): 2902-12. [PMID:24659881] |